Business Wire

Ferring Announces Ground-Breaking and Inclusive Family Building Benefits Package for All Its Employees Globally

14.7.2022 08:00:00 EEST | Business Wire | Press release

Share

Ferring Pharmaceuticals is committed to building families of every shape and size. As part of this commitment, Ferring has announced the introduction of a new global family building benefits package for its employees. The holistic three-tier support model provides family building financial benefits, a ground-breaking 26-week global minimum standard of equal paid parental leave for both birthing and non-birthing parents as well as increased awareness and support at work.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220707005467/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Infographic: Business Wire)

The comprehensive package recognises the complexities of building a family and aims to enable different family building options by removing the financial barriers and providing access to quality care. Unlimited financial assistance is provided within the scope of its providers’ services.

Ferring’s support package provides equal opportunities to becoming a parent regardless of medical need, personal circumstances or family structure. This means providing the financial support required to access fertility treatments, surrogacy programmes, adoption, egg freezing, counselling and related services. Additionally, to ensure employees feel supported during the process of their family building journey, paid leave is available for fertility treatment and adoption procedures.

Building on the long-standing fertility benefits package offered to its US-based employees via its provider, Progyny, Ferring has now engaged Carrot, to support its employees in the rest of the world.

Infertility is a significant clinical issue, estimated to affect 1 in 6 heterosexual couples globally.1,2 Research has found that the negative impacts of infertility are profound and a clear gap exists between the number of people who experience mental health issues due to infertility and the number seeking help to address these mental health issues.3 Underlying the practical support provided by the new package will be support for employees’ emotional wellbeing, with four weeks paid leave provided for miscarriage for example, and counselling services offered to all employees from the outset of their fertility journey.

“At Ferring we commit to advocating for everyone’s right to build a family, no matter who you are, where you live or who you love. The new family building support package ensures a global standard for support irrespective of location, role or family circumstances. It makes no assumptions about gender, sexual orientation or relationship status, or about parental roles or responsibilities in the early stages of childcare,” said Christelle Beneteau, Executive Committee member and Chief Human Resources Officer at Ferring Pharmaceuticals.

Christelle added: “As we strive to lead by example in becoming a fertility and family friendly employer, I’m immensely proud of this world-leading, comprehensive and inclusive package. All of our employees collectively contribute to advancing our mission to build families and help people live better lives. We want to do everything we can to support them in their own family building journeys, removing barriers and provide an environment in which they are empowered to focus on their families at this important time.”

As a leading global healthcare company in reproductive medicine and maternal health, Ferring aims to advance its #ProjectFamily Commitment by creating a fertility and family friendly experience at work and increase awareness of the experiences of family building journeys and to foster support, respect and understanding in all its workplaces. Through training, awareness events and open dialogue, Ferring will ensure that its new family building support package goes further than financial assistance or leave policies and creates a world leading family and fertility friendly workplace.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in more than 50 countries, and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

Note: The availability of financial support and access to some benefits is subject to compliance with local laws.

# # #

References:

1 European Society of Human Reproduction and Embryology, ART Factsheet 2018. Available at: https://www.eshre.eu/Press-Room/Resources. Last accessed March 2022.

2 World Health Organization. Infertility. Available https://www.who.int/health-topics/infertility#tab=tab_1. Last accessed March 2022.

3 Boivin J et al. Tailored support may be required to reduce the impact of the infertility journey on mental health, relationships and daily lives of infertile patients and partners to infertile patients. Reproductive Biomedicine online. March 2022. DOI: https://doi.org/10.1016/j.rbmo.2022.01.015

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information, please contact

Yasmin Gharib
Account Director, Syneos Health Communications PR Europe
+44 (0)7788 663 999 (mobile)
yasmin.gharib@syneoshealth.com

A dam Alexander
Senior Account Executive, Syneos Health Communications PR Europe
+44 785 469 4245 (mobile)
adam.alexander@syneoshealth.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 10:00:00 EEST | Press release

Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and support, the Westcoast partnership helps cut the ‘meeting tax’, reducing set‑up friction and getting meetings started on time. The announc

Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 10:00:00 EEST | Press release

Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the freedom to book their own trips without getting bogged down in manual approvals. Navan gives t

Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 10:00:00 EEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic

Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 202611.5.2026 09:00:00 EEST | Press release

Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/ The MEVION S250-FIT™ Proton Therapy System Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology. Stanford Medicine: First S250-FIT Installation On April 7, 2026, Stanford Medicine unveiled the world’s first S250-FIT installation, developed in collaboration with Leo Cancer Care. The system was fully installed within a stan

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results11.5.2026 08:10:00 EEST | Press release

Business Updates section, the first bullet of release dated April 23, 2026, at 10:04 p.m. PT/April 24, 2026, at 1:04 a.m. ET should read: In October 2025, Samsung Bioepis entered into a private label partnership with Cordavis for OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia1. The updated release reads: SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye